vs
Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1M | — | ||
| Q3 25 | $260.0K | — | ||
| Q2 25 | $518.0K | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $115.0K | — | ||
| Q2 24 | $104.0K | — | ||
| Q1 24 | $176.0K | — |
| Q4 25 | $-23.0M | — | ||
| Q3 25 | $-10.9M | — | ||
| Q2 25 | $-9.7M | — | ||
| Q1 25 | $-6.7M | — | ||
| Q4 24 | $-33.5M | — | ||
| Q3 24 | $-13.5M | — | ||
| Q2 24 | $-4.5M | — | ||
| Q1 24 | $-9.1M | — |
| Q4 25 | 42.5% | — | ||
| Q3 25 | 53.5% | — | ||
| Q2 25 | 67.6% | — | ||
| Q1 25 | 62.0% | — | ||
| Q4 24 | 40.0% | — | ||
| Q3 24 | 43.5% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 25.6% | — |
| Q4 25 | -2057.5% | — | ||
| Q3 25 | -4249.2% | — | ||
| Q2 25 | -1900.0% | — | ||
| Q1 25 | -318.0% | — | ||
| Q4 24 | -2262.9% | — | ||
| Q3 24 | -11752.2% | — | ||
| Q2 24 | -4453.8% | — | ||
| Q1 24 | -5265.3% | — |
| Q4 25 | -2015.4% | — | ||
| Q3 25 | -4174.6% | — | ||
| Q2 25 | -1880.7% | — | ||
| Q1 25 | -312.0% | — | ||
| Q4 24 | -2255.1% | — | ||
| Q3 24 | -11733.0% | — | ||
| Q2 24 | -4355.8% | — | ||
| Q1 24 | -5186.9% | — |
| Q4 25 | $-0.75 | — | ||
| Q3 25 | $-0.34 | — | ||
| Q2 25 | $-0.30 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | $-2.19 | — | ||
| Q3 24 | $-0.98 | — | ||
| Q2 24 | $-0.36 | — | ||
| Q1 24 | $-1.13 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
